Solid forms of emetine
Crystalline forms of emetine dihydrochloride (Compound I dihydrochloride) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms of Compound I dihydrochloride.
1 . A method of treating a viral infection in a subject in need thereof, the method comprising:
administering to the patient a therapeutically effective amount of a crystalline form of Compound I dihydrochloride having the formula:
selected from: Compound I dihydrochloride Form 7B; Compound I dihydrochloride Form 2; Compound I dihydrochloride Form 3; Compound I dihydrochloride Form 4; Compound I dihydrochloride Form 5; Compound I dihydrochloride Form 6; Compound I dihydrochloride Form 7A; and Compound I dihydrochloride Form 8;
wherein the therapeutically effective amount of the crystalline form of Compound I dihydrochloride ranges from 1 to 1000 mg.
2 . The method of claim 1 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is 1 mg to about 500 mg per day.
3 . The method of claim 1 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is 1 mg to about 50 mg per day.
4 . The method of claim 1 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is 100 mg per day.
5 . The method of claim 1 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is 50 mg per day.
6 . The method of claim 1 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is 1 mg per day.
7 . The method of claim 1 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is about 1 mg to about 70 mg per day.
8 . The method of claim 1 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is about 3 mg to about 65 mg per day.
9 . The method of claim 1 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is about 5 mg to about 10 mg per day.
10 . The method of claim 1 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is about 10 mg.
11 . The method of claim 1 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is about 50 mg.
12 . The method of claim 1 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is about 100 mg.
13 . The method of claim 1 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is about 150 mg.
14 . The method of claim 1 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is about 10 mg to about 175 mg.
15 . A method of treating a viral infection in a subject in need thereof, the method comprising:
administering to the patient a therapeutically effective amount of a crystalline form of Compound I dihydrochloride having the formula:
selected from: Compound I dihydrochloride Form 7B; Compound I dihydrochloride Form 2; Compound I dihydrochloride Form 3; Compound I dihydrochloride Form 4; Compound I dihydrochloride Form 5; Compound I dihydrochloride Form 6; Compound I dihydrochloride Form 7A; and Compound I dihydrochloride Form 8;
wherein the patient in need thereof is administered a daily dose ranging from 1 to 1000 mg of the crystalline form of Compound I dihydrochloride; and
wherein one or more additional therapeutic agents is administered to the patient in need thereof.
16 . The method of claim 15 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is 1 mg to about 500 mg per day.
17 . The method of claim 15 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is 1 mg to about 50 mg per day.
18 . The method of claim 15 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is 100 mg per day.
19 . The method of claim 15 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is 50 mg per day.
20 . The method of claim 15 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is 1 mg per day.
21 . The method of claim 15 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is about 1 mg to about 70 mg per day.
22 . The method of claim 15 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is about 3 mg to about 65 mg per day.
23 . The method of claim 15 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is about 5 mg to about 10 mg per day.
24 . The method of claim 15 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is about 10 mg.
25 . The method of claim 15 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is about 50 mg.
26 . The method of claim 15 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is about 100 mg.
27 . The method of claim 15 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is about 150 mg.
28 . The method of claim 15 , wherein the therapeutically effective amount of a crystalline form of Compound I dihydrochloride is about 10 mg to about 175 mg.